Alarming Rise of Primary HIV Drug Resistance in Major Regions of Russia

Dmitry      Kireev; Alina      Kirichenko; Aleksey      Lebedev; Marina      Bobkova

Abstract

Objective: The study aimed to compare the prevalence of surveillance HIV drug resistance mutations (SDRMs) across the main federal districts of Russia.

Methods: A pooled analysis was conducted to examine data on HIV primary drug resistance (HIV PrimDR). The analysis was based on published results primarily from Russian regional clinical and scientific laboratories, covering a span of 20 years.

Results: The findings indicate that three surveyed regions, namely Central, Far Eastern, and Volga, exhibit a low level of HIV PrimDR prevalence (not exceeding 5%), and this prevalence does not show a tendency to increase. In contrast, three major regions, namely Northwestern, Southern, and Siberian, demonstrate a significant and progressive increase in HIV PrimDR prevalence, with recent values surpassing 10%.

Conclusion: Consequently, it was concluded that a change in the HIV treatment strategy in these regions is imperative, emphasizing the need to expedite the transition to the utilization of secondgeneration integrase inhibitors.

[1]
UNAIDS Data. 2022. Available from: https://www.unaids.org/sites/default/files/media_asset/data-book-2022_en.pdf

[2]
Rospotrebnadzor. State report "On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022. 2023. Available from: https://www.rospotrebnadzor.ru/upload/iblock/b50/t4kqksh4b12a2iwjnha29922vu7naki5/GDSEB.pdf

[3]
Rospotrebnadzor. Information "HIV infection in the Russian Federation as of December 31, 2021. 2022. Available from: http://www.hivrussia.info/wp-content/uploads/2022/03/SpravkaVICH-v-Rossii-na-31.12.2021-g.pdf

[4]
Treatment preparedness coalition. Analysis of procurement of ARV drugs in the Russian federation 2021. Available from: https://itpc-eeca.org/wpcontent/uploads/2022/07/otchet_po_monitoringu_goszakupok_arvp_vich_2021_god_pdf.pdf

[5]
Bobkova MR, Grezina LA, Dementieva NE, et al. Clinical guidelines "HIV drug resistance analysis. Laboratory Service  6(3): 217-37.

[6]
Surveillance of the spread of antiretroviral resistant HIV strains. 2013.https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=1405

[7]
Russian Ministry of health. Clinical guidelines "HIV infection in adults" 2020. 2020.https://cr.minzdrav.gov.ru/recomend/79_1

[8]
Kirichenko A, Kireev D, Lapovok I, et al. HIV-1 Drug Resistance among Treatment-Naive Patients in Russia: Analysis of the National Database, 2006-2022. Viruses  2023; 15(4)

[9]
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One  2009; 4(3): e4724.

[10]
Antonova A. HIV molecular epidemiology and new treatment strategies in Russia CARE Consortium virtual meeting. Russian 2021.

[11]
Antonova АА, Tumanov АS, Lebedev АV, et al. Genetic profile and characteristics of HIV-1 drug resistance mutation in the Krasnodar region over the 2014 to 2019. Vichinfektsiia Immunosuppr  2022; 14(2): 20-30.
 [http://dx.doi.org/10.22328/2077-9828-2022-14-2-20-30]

[12]
Bogoslovskaya E, Shipulin G. Prevalence of primary resistance to HIV antiretroviral drugs in HIV-infected patients in Moscow and Moscow region. Emerg Infect Dis  2007; 2007(6): 39-42.

[13]
Dementyeva N. Drug resistance in HIV-infected patients in St. Petersburg. III St Petersburg Forum on HIV infection. St Petersburg. 2018.October 4-5, 2018; 

[14]
Gashnikova NM, Astakhova EM, Gashnikova MP, et al. HIV-1 epidemiology, genetic diversity, and primary drug resistance in the Tyumen oblast, Russia. BioMed Res Int  2016; 2016: 1-13.
 [http://dx.doi.org/10.1155/2016/2496280] [PMID: 27957489]

[15]
Gashnikova N, Totmenin A, Saukhat S, et al. Molecular-epidemiological characteristics of the spread of HIV-infection in the south of Russia. HIV Infection and Immunosuppressive Disorders  2013; 5(4): 73-81.

[16]
Ingabire T, Semenov AV, Esaulenko EV, Zueva EB, Schemelev AN, Bushmanova AD. Primary HIV drug resistance among newly HIV type-1 diagnosed patients in St. Petersburg. Vichinfektsiia Immunosuppr  2021; 13(1): 70-9.
 [http://dx.doi.org/10.22328/2077-9828-2021-13-1-70-79]

[17]
Kapustin D, Krasnova E, Khalikov M, et al. Analysis of the prevalence of primary resistance of HIV-1 for antiretroviral drugs in the Novosibirsk region. Therapy  2022; 8(3): 35-41.
 [http://dx.doi.org/10.18565/therapy.2022.3.35-41]

[18]
Kazennova EV, Antonova AA, Ozhmegova EN, et al. Genetic analysis of HIV-1 in the Altai Kray: the further spread of the CRF6302A1 variant in Western Siberia. Vichinfektsiia Immunosuppr  2020; 12(1): 47-57.
 [http://dx.doi.org/10.22328/2077-9828-2020-12-1-47-57]

[19]
Kazennova E, Laga V, Gromov K. Molecular epidemiological analysis of hiv infection in northern seaports of Russia. Vopr Virusol  2017; 62(4): 154-61.
 [http://dx.doi.org/10.18821/0507-4088-2017-62-4-154-161]

[20]
Kazennova E, Lapovok I, Lebedev A. Analysis of HIV drugs resistance in Volga
          federal district of the Russian federation.. HIV Infection and Immunosuppressive Disorders  2015; 7(3): 56-65.

[21]
Kolomeets A, Rubina Y, Yarusova I. Molecular genetic features of HIV in infected persons in the Siberian federal district in 2015. National priorities of Russia  2017; 4(26): 71-6.

[22]
Kolomeets A, Varghese V, Lemey P, Bobkova M, Shafer R. Epidemiological and molecular genetic features of HIV in infected persons on the territory of the Siberian federal district. Med J  2016; 1(18): 16-20.

[23]
Kotova I, Balakhontseva L, Ivanov A. Primary resistance of HIV to antiretroviral drugs in HIV-infected patients in the Far Eastern federal district. Far Eastern Journal of Infectious Pathology  2010; (17): 82-6.

[24]
Kotova I, Balakhontseva L, Ivanov A, Trotsenko O. Prevalence of drug-resistant HIV strains in HIV-infected patients in the Far Eastern federal distric. Far Eastern Journal of Infectious Pathology  2012; (21): 89-92.

[25]
Kotova VO, Balakhontseva LA, Trotsenko OE. Analysis of HIV-1 drug resistance in the regions of Far Eastern federal district. Vichinfektsiia Immunosuppr  2016; 8(3): 53-8.
 [http://dx.doi.org/10.22328/2077-9828-2016-8-3-53-58]

[26]
Kotova V, Trotsenko O, Balakhontseva L, Bazykina E. Molecular genetic characteristics of HIV-1 variants isolated in Far Eastern federal district. Probl Virol  2019; 64(2): 79-89.
 [http://dx.doi.org/10.18821/0507-4088-2019-64-2-79-89] [PMID: 31412174]

[27]
Kotova V, Trotsenko O, Balakhontseva L. Molecular-epidemiological characteristics of HIV-1 variants circulating in the Jewish autonomous region territory. HIV Infection and Immunosuppressive Disorders  2018; 10(4): 90-9.

[28]
Lebedev AV, Neshumaev DA, Kazennova EV, et al. Comparative analysis of genetic variants of the HIV-1 circulating in the Irkutsk region in 1999 and 2012. Probl Virol  2016; 61(3): 112-8.3) 
 [http://dx.doi.org/10.18821/0507-4088-2016-61-3-112-118] [PMID: 36494944]

[29]
Musatov V, Yakovlev A, Tyrgina TV, Ladnaya N. Prognostic value of the results of genotyping of human immunodeficiency viruses isolated from patients with primary HIV infection in 2009 and 2011 in St. Petersburg. Bulletin of St. Petersburg university. Series 11. Medicine  2013; 171-8.

[30]
Nosik MN, Ryzhov KA, Kravchenko AV, et al. Analysis of prevalence of HIV-1 primary resistance to antiretroviral drugs in the territory of Moscow and Moscow region. J Microbiol epidemiology Immunol Infect  2019; 96(3): 27-31.
 [http://dx.doi.org/10.36233/0372-9311-2019-3-27-31]

[31]
Parfenova OV, Peksheva OY, Zaitsevа NN. Spread of mutations of resistance and HIV-1 subtypes as an indicator of dynamics of HIV epidemic in the Volga federal district in 2016–2018. Public Healt Life Environ  2019; 8(317): 50-5.
 [http://dx.doi.org/10.35627/2219-5238/2019-317-8-50-55]

[32]
Pasechnik O. Personal communication. Siberian AIDS center 2023.

[33]
Rudometova NB, Shcherbakova NS, Shcherbakov DN, et al. Genetic diversity and drug resistance mutations in reverse transcriptase and protease genes of HIV-1 isolates from southwestern siberia. AIDS Res Hum Retroviruses  2021; 37(9): 716-23.
 [http://dx.doi.org/10.1089/aid.2020.0225] [PMID: 33677988]

[34]
Rumyantseva OA, Olkhovskiy IA, Malysheva MA, et al. Epidemiological networks and drug resistance of HIV type 1 in Krasnoyarsk region, Russia. AIDS Res Hum Retroviruses  2009; 25(9): 931-6.
 [http://dx.doi.org/10.1089/aid.2009.0075] [PMID: 19689192]

[35]
Ryzhov K, Nosik M, Rymanova I. Prevalence of mutations leading to HIV-1 resistance to antiretroviral drugs. Molecular Diagnostics conference proceedings. Moscow. 2017.

[36]
Samarina A, Martirosyan M, Sizova N, Dementieva N, Belyakov N. Effectiveness of chemoprophylaxis and HIV drug resistance in infected pregnant women. HIV Infection and Immunosuppressive Disorders.  4(3): 28-34.

[37]
Schlösser M, Kartashev V, Mikkola V, Eds. Molecular epidemiology of HIV-1 in South Russia and neighbouring regions. HIV Glasgow 2018; JIAS  2018; 21(S8): e25187.

[38]
Schlösser M, Kartashev V, Mikkola V. HIV-1 sub-subtype A6: Settings for normalised identification and molecular epidemiology in the southern federal district, Russia. Viruses  2020; 12(4): 475.

[39]
Shchemelev AN, Semenov AV, Ostankova YV, et al. Genetic diversity of the human immunodeficiency virus (HIV-1) in the Kaliningrad region. Probl Virol  2022; 67(4): 310-21.
 [http://dx.doi.org/10.36233/0507-4088-119] [PMID: 36097712]

[40]
Shemelev A. Incidence of HIV drug resistance in St. Petersburg and Leningrad region in patients with inefficient therapy and not taking treatment. XI interregional scientific and practical Internet conference of young scientists and specialists of Rospotrebnadzor with international participation. Saratov. 2021.

[41]
Shemshura A, Poddubskaya S, Svechnikova L, et al. Spread of resistance mutations to HIV-l reverse transcriptase inhibitors among HIV-infected patients of the Southern federal district. Clin Lab Diag  2007; 1: 42-6.

[42]
Vorontsova G, Kuznetsova A, Ushakova V, et al. Prevalence of primary drug HIV-1 resistance in Khabarovsk Krai. Far Eastern State Medical University proceedings  2015; 54-7.

[43]
Zaitseva N, Peksheva O, Parfenova O, Butina T, Kuznetsova I. Modern molecular genetic research methods in the characterization of HIV-1 isolates of infected patients in penitentiary institutions. Medical Almanac  2015; 5(40): 148-51.

[44]
Zaytseva N, Parfenova O, Peksheva O. Analysis of the prevalence of primary resistance of HIV to antiretroviral drugs in the Volga federal district. Medical Almanac  2016; 3(43): 93-5.
 [http://dx.doi.org/10.21145/2499-9954-2016-3-93-95]

[45]
Zyryanova D, Astakhova E, Gashnikova M, et al. Detection of HIV-1 resistant to antiretrovirals drugs among the residents of the Tomsk region first diagnosed with HIV. J Infect  2020; 12(2): 88-96.

[46]
Russian Unified interdepartmental information and statistical system. Official statistics. 2020.2023. Available from: https://www.fedstat.ru/

[47]
Russian Federal State Statistics Service (ROSSTAT).. Socio-economic situation in Russia. 2022. Available from: https://gks.ru/bgd/regl/b22_01/Main.htm

[48]
Rospotrebnadzor. HIV infection. News bulletin № 47. 2023. Available from: http://www.hivrussia.info/wp-content/uploads/2023/05/Byulleten-47-VICH-infektsiya-za-2021g.pdf

[49]
Kozyrina NV, Ladnaya NNV, Kravchenko AV. Health care coverage among people living with HIV in 2021 in the Russian Federation. Proceedings of the XV Annual All-Russian Congress on Infectious Diseases named after Academician VI Pokrovsky. March 27–29, 2023; Moscow. 

[50]
Lebedeva NN, Zverev SYa, Kulagin VV, et al. HIV drug resistance early warning indicators and their assessment in some regions of RUSSIA. HIV Infection and Immunosuppressive Disorders  2018; 10(4): 67-75.

[51]
WHO. Global action plan on HIV drug resistance 2017–2021. 2019. Available from: https://www.who.int/hiv/pub/drugresistance/hivdr-action-plan-2017-2021/en/

Cite As

Current HIV Research

Alarming Rise of Primary HIV Drug Resistance in Major Regions of Russia

Abstract